Whole lung Irradiation as a Novel treatment for COVID-19 - WIN COVID-19

Harshamitra Superspecialty Cancer Centre and Research Institute0 个研究点目标入组 61 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Adult patients with RT-PCR proven COVID-19 with moderate to severe pneumonia with fewer than 14 days of symptom onset that warranted hospitalization and currently receiving standard medication for COVID-19 at appropriate doses which would include, among others, antivirals, corticosteroids, or anti-IL-6 tocilizumab.
•2. moderate to severe dyspnoea, respiratory frequency equal to or greater than 30/min, oxygen saturation without supplemental O2 supply SpO2 94% or less, PaO2/FiO2 ratio or PaFiO2 ratio between 200 to 300 or SpO2/FiO2 ratio 315 or less if PaO2 is not available
•3. laboratory abnormalities such as C-reactive protein >100 mg/L or D-dimer >1000 ng/ml or IL-6 >50 IU or suspected cytokine release syndrome
•(Criteria 1 and 2 are mandatory and 3 is optional)

•1. Patients on ventilators (invasive/non-invasive)
•2. Prior lobectomy or pneumonectomy
•3. Prior thoracic radiotherapy resulting in a maximum lung dose of 100 cGy or higher within 14 days of enrollment
•4. Prior chemotherapy or other systemic therapy with potential for pulmonary toxicity or radio sensitization within 14 days or 5 half-lives, whichever is greater, of enrollment, e.g., bleomycin, gemcitabine
•5. Prior cancer immunotherapy with an immune checkpoint inhibitor within 60 days of enrollment
•6. Severe pre-existing heart disease, e.g., New York Heart Association (NYHA) functional class 3 (or higher) congestive heart failure
•7. History of bone marrow or solid organ transplantation
•8. Known history of autoimmune collagen vascular disease, e.g., scleroderma
•9. Known hereditary syndrome with increased sensitivity to ionizing radiation, e.g., ataxia-telangiectasia or Fanconi anemia
•10. Pregnancy
•11. Inability to be positioned supine and flat for radiation planning and delivery
•12. Inability to provide informed consent or lack of an authorized representative who can provide informed consent

发起方

Harshamitra Superspecialty Cancer Centre and Research Institute